Repare Therapeutics’ Post

Our team is looking forward to connecting with leading clinicians and researchers and to discussing the latest progress in #GIcancer at the ESMO - European Society for Medical Oncology Gastrointestinal Cancers Congress. Ulixertinib, our highly selective, first-in-class ERK 1/2 inhibitor, is being evaluated in combination with hydroxychloroquine in individuals with advanced gastrointestinal malignancies, including cholangiocarcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Learn more about the study: https://lnkd.in/eNbpDbJW #ESMOGI24 #MAPK

2023 updated MASCC and ESMO - European Society for Medical Oncology recommendations for prophylaxis of nausea and vomiting - Erman Akkus, MD The Multinational Association of Supportive Care in Cancer (MASCC) #Aprepitant #Cancer #Cisplatin #Dexamethasone #ESMO #MASCC #Olanzapin #OncoDaily #Oncology

Small Contribution in the world of oncology care has just been published! newly released book chapter titled "Somatic Mutations: Pharmacogenomic in Oncology Care." Dive into the world of cutting-edge research and explore the intricate relationship between somatic mutations and pharmacogenomics. Our chapter delves into the latest advancements that promise to revolutionize oncology care. #OncologyCare #ResearchMilestone #Pharmacogenomics #SomaticMutations #MedicalBreakthroughshttps https://lnkd.in/gp4HAiQa

During the #ASH2023 Meeting, Oluwatobi Odetola, MD, Northwestern University - The Feinberg School of Medicine, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk #DLBCL. Learn more: https://lnkd.in/eyfPks2x #ASH #Oncology #OncologyNews #Lymphoma #OncologyResearch

Looking forward to the research that will be shared at ASCO GU later this week, including the culmination of a project I had the honor of working on with Mihaela Georgiana Musat, Hoora Moradian, PhD, Ioana Gulas, Mairead Kearney, Silke Guenther, Srikala S. Sridhar, and Richard O'Dwyer: Clinical outcomes with split-dose cisplatin-based regimens in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a systematic literature review (SLR) and network meta-analysis (NMA).

News SOC in first line mUC advancing by leaps and bounds. Today, 15th december, FDA has approved pembrolizumab plus enfortumab vedotin as 1st line treatment for patients with locally advanced or metastatic urothelial carcinoma, due to EV302/K-A39 phase 3 trial. ✅54.3% cisplatin elegible ✅71.9% visceral metastasis (22.6% liver) ✅mOS 31.5 vs 16.1 m (HR 0.47, 95% CI: 0.38-0.58)➡️HR 0.53 cis-eligible, HR 0.43 cis-ineligible ✅mPFS 12.5 vs 6.3 m (HR 0.45,95% CI: 0.38-0.45) ✅ORR 67.7 vs 44.4% (CR 29.1 vs 12.5%; PD 8.7 vs 13.6%) ✅30.4 % avelumab maintenance control arm ✅22 vs 14% discontinuations ✅AEs G3 and higher: 56 vs 70% Thoughts: 🙌 mOS never previously seen 👁️ 31.5 m from EV302 > 23.8 m (25.3 m in ciseligible population) in JAVELIN100, 29.7 m from start of 1L chemotherapy > 21.7 m (CGnivo-Checkmate901 ciseligible) 🥷Probably we need to get used to AES management and probably there will still be a room for some JAVELIN patients.

Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study Antonio Passaro American Society of Clinical Oncology (ASCO) #ASCO24 #Cancer #NSCLC #LCsm #ClinicalTrials #OncoDaily #Oncology

I want to thank patients, investigators and their staff for participating in our clinical trial with monotherapy #roginolisib, which was presented by #AnnaMariaDiGiacomo at this year´s Annual Meeting of the American Society of Clinical Oncology (#ASCO2024) in Chicago (see https://lnkd.in/dFpfc_cX; also see: ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers" | VuMedi).  We are excited to learn more about the activity of roginolisib in patients with metastatic uveal melanoma as we continue to analyze the biomarker data from patients treated with #roginolisib. Such data will be presented at future medical conferences.

Ever wondered how science meets personalized care? Meet the Oncotype DX Breast Recurrence Score® test – your trusted companion in the fight against breast cancer. 🧬✨ This groundbreaking test dives deep into the unique genetic makeup of your early-stage breast cancer tumor, providing personalized insights that help guide your treatment journey. No two cancers are the same, and neither should be your approach to beating it! With the Oncotype DX® test, your healthcare provider gets tailored information, letting you know if chemotherapy is appropriate for you, empowering you and your medical team to make the most informed decisions about YOUR health. 🎗️💖 Knowledge is power, and in this battle, it's your greatest weapon. Feel confident, stay informed, and let’s face this challenge head-on, together! 💫 https://lnkd.in/eYX38ftp #OncotypeDX #PersonalizedCare #CancerWarriors #KnowledgeIsPower #UntilEveryoneKnows #EmpowerYourCancerJourney

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting has officially commenced! This year, KCR provided data to support 11 abstracts selected by the conference’s scientific committee, testifying to the #quality and impact of the #research conducted by our organization. Our team was honored to join 40,000 oncologists from around the world for the reveal of #results from the most innovative #clinical studies recently conducted. They key takeaway? KCR Chief Medical Officer, Anna Baran highlighted the results of the NADINA trial that demonstrates the benefit of neoadjuvant ipilimumab plus nivolumab, followed by adjuvant therapy if no response, over the adjuvant nivolumab alone in stage III melanoma. 💡 The results could create a new paradigm for other malignancies, and present new possibilities for #immunotherapy regimens moving forward. Stay tuned for more #conference wrap up next week. Until next time! #KCRCRO #ASCO #Oncology #CancerCare #Research #Chicago #ASCO24 #ASCO2024